Theratechnologies (NASDAQ:THTX) Posts Earnings Results

Theratechnologies (NASDAQ:THTX) announced its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03), Fidelity Earnings reports. Theratechnologies had a negative net margin of 37.10% and a negative return on equity of 112.84%. During the same quarter last year, the firm earned ($0.09) EPS.

Shares of THTX stock opened at $3.57 on Thursday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.74 and a current ratio of 2.41. The stock has a market capitalization of $338.13 million, a P/E ratio of -11.90 and a beta of 1.65. The company has a 50 day moving average price of $3.61 and a 200 day moving average price of $3.63. Theratechnologies has a fifty-two week low of $1.83 and a fifty-two week high of $4.46.

A number of equities research analysts have weighed in on THTX shares. Zacks Investment Research upgraded shares of Theratechnologies from a “sell” rating to a “hold” rating in a research report on Wednesday, September 15th. Canaccord Genuity cut shares of Theratechnologies from a “buy” rating to a “hold” rating and dropped their price objective for the company from $8.00 to $3.00 in a report on Thursday, July 29th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Theratechnologies presently has an average rating of “Hold” and an average target price of $3.17.

An institutional investor recently raised its position in Theratechnologies stock. Morgan Stanley raised its position in Theratechnologies Inc. (NASDAQ:THTX) by 143.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,716,512 shares of the company’s stock after acquiring an additional 1,012,777 shares during the quarter. Morgan Stanley owned approximately 1.81% of Theratechnologies worth $6,660,000 as of its most recent SEC filing. Institutional investors and hedge funds own 19.29% of the company’s stock.

Theratechnologies Company Profile

Theratechnologies, Inc is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Read More: How are institutional investors different from individual investors?

Earnings History for Theratechnologies (NASDAQ:THTX)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.